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Summary The tumour blood flow inhibitor 5,6-dimethylxanthenone-4-acetic acid (DMXAA) causes dramatic haemorrhagic necrosis in murine
tumours, but activity is seen only at doses close to the toxic limit. This study investigates two approaches for increasing the therapeutic ratio
of DMXAA. The first approach combines DMXAA with a second tumour blood flow inhibitor, 5-hydroxytryptamine (5-HT). Co-administration of
5-HT (700,mol kg-1) to C3H mice caused marked enhancement of DMXAA effects against MDAH-MCa-4 tumours, with dose-modifying
factors (DMFs) of >3 for blood flow inhibition (at 4 h), 2.3 for necrosis (at 12 h) and 2.0 for growth delay, without compromising the maximum
tolerated dose of DMXAA (90 gmol kg-'). The data are consistent with ischaemic injury to the tumour being the major mechanism of anti-
tumour activity. The second approach combines DMXAA (± 5-HT) with hypoxia-selective bioreductive drugs. Anti-tumour activity of all three
bioreductive drugs tested (tirapazamine, Cl-1010, SN 23816) was strongly potentiated by DMXAA, suggesting that there is a population of
reversibly hypoxic tumour cells after DMXAA treatment. Co-administration of 5-HT further potentiated anti-tumour activity, but also increased
host toxicity of tirapazamine and Cl-1010 so that little therapeutic benefit was achieved. In contrast, the host toxicity of the dinitrobenzamide
mustard SN 23816 was only slightly increased by DMXAAI5-HT, whereas the tumour growth delay at the maximum tolerated dose of SN
23816 was increased from 3.5 to 26.5 days. This study demonstrates that 5-HT and/or bioreductive drugs can improve the therapeutic activity
of DMXAA in mice, and that with SN 23816 both approaches can be used together to provide considerably enhanced anti-tumour activity.
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5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent
analogue of flavone-8-acetic acid (FAA), is currently in phase I
clinical trial as an anti-cancer agent. Like FAA, DMXAA causes
protracted inhibition ofblood flow in murine tumours (Cliffe et al,
1994; Zwi et al, 1994a) leading to extensive haemorrhagic
necrosis (Rewcastle et al, 1991; Zwi et al, 1994b). The mechanism
of blood flow inhibition is not fully understood, but DMXAA
induces a variety of bioactive products including tumour necrosis
factor alpha (TNF-a), interferons, interferon regulatory factors,
IP-10, nitric oxide and serotonin (Baguley and Ching, 1997). In
the case ofFAA, there is strong evidence that TNF-oc is the major
mediator of the antivascular effects (Mahadevan et al, 1990). The
disappointing lack of activity of FAA in humans (Kerr and Kaye,
1989; O'Reilly et al, 1993) may reflect a mouse-human species
difference as FAA has been shown to be considerably less effec-
tive in inducing TNF-a in human than mouse haematopoietic cells
(Futami et al, 1991; Ching et al, 1994). In contrast, DMXAA is
similarly active as a TNF-oc inducer against cells of either species
(Ching et al, 1994), and unlike FAA is able to induce TNF-a
synthesis by human peripheral blood leucocytes in vitro (Philpott
et al, 1997).
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Although DMXAA shows dramatic activity against advanced
solid tumours in mice, several studies have noted its narrow thera-
peutic window, with significant anti-tumour activity and cytokine
induction seen only at doses close to the MTD (Baguley et al,
1993; Zwi et al, 1994a; Laws et al, 1995; Pedley et al, 1996). This
low therapeutic ratio may make it difficult to use DMXAA as a
single agent in humans. The present study examines two
approaches with potential for improving the therapeutic utility of
DMXAA. The first is to combine DMXAA with 5-hydroxytrypta-
mine (5-HT). 5-HT is known to inhibit tumour blood flow in mice
(Peters and Chaplin, 1992), providing preferential vasoconstric-
tion in arterioles supplying tumour tissue (Stucker et al, 1991).
Baguley et al (1993) have shown that administration of5-HT with
a subtherapeutic dose of DMXAA (66 ,umol kg-') enhances
growth inhibition of the colon 38 tumour, and similar effects have
been observed with a human colon carcinoma xenograft (Pedley et
al, 1996). In the present study the potential ofexogenously admin-
istered 5-HT to enhance the therapeutic activity of DMXAA is
investigated using an early-passage, non-immunogenic (Moselen
et al, 1995) murine breast carcinoma (MDAH-MCa-4). Three end
points (tumour blood flow inhibition, necrosis and growth delay)
are compared to explore further the role of blood flow inhibition
in the anti-tumour activity of DMXAA and DMXAA/5-HT
combinations.
The second approach examined here for improving the thera-
peutic ratio of DMXAA is to exploit the additional hypoxia
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induced by blood flow inhibition to increase the metabolic activa-
tion of a bioreductive drug in the tumour. This concept was first
demonstrated by the enhancement of activity of the 2-nitroimida-
zole alkylating agent RSU 1069 against Lewis lung tumours by
5-HT (Chaplin, 1986). Several subsequent studies have demon-
strated therapeutic synergism when bioreductive drugs are
combined with TNF-ax (Edwards et al, 1991), FAA (Sun and
Brown, 1989; Edwards et al, 1991; Cliffe et al, 1994), DMXAA
(Cliffe et al, 1994; Wilson and Pruijn, 1995; Wilson et al, 1996;
Vincent et al, 1997) or other antivascular treatments such as 'early'
photodynamic therapy (Bremner et al, 1992). In the present study
the potential for combining DMXAA/5-HT with bioreductive
drugs is explored using examples of three different bioreductive
drug classes. The compounds examined are tirapazamine (TIRA),
a benzotriazine-di-N-oxide (Brown, 1993), CI-1010 (the R-enan-
tiomer of RB 6145), which is a prodrug form of RSU 1069
(Jenkins et al, 1990; Adams and Stratford, 1994), and SN 23816
(NSC 646394), which is a 2,4-dinitrobenzamide nitrogen mustard
related to CB 1954 (Palmer et al, 1992, 1994).
MATERIALS AND METHODS
Compounds
DMXAA (sodium salt), TIRA and SN 23816 were synthesized in
the Cancer Research Laboratory, Auckland, and CI-1010 was a
gift from Parke Davis Pharmaceutical Research, Ann Arbor, MI,
USA. DMXAA was dissolved in phosphate-buffered saline (PBS)
and stored frozen, with protection from light at all times
(Rewcastle et al, 1990). TIRA was formulated in 10%
DMSO/water, SN 23816 in PBS and CI-1010 in 0.05 N sodium
lactate buffer, pH 4.0. 5-HT (sodium chloride salt) was purchased
from Sigma and solutions in PBS were frozen until use.
Host toxicity and anti-tumour activity
Mice were C3H/HeN females, 22-25 g at the time of treatment,
bred under specific pathogen-free conditions in the Animal
Resources Unit, The University of Auckland. Host toxicity was
assessed by determining the maximum tolerated dose (MTD),
using approximately 1.3-fold dose increments. For non-tumour-
bearing mice the MTD was defined as the highest dose that did not
cause any deaths or severe morbidity in a group of six mice, using
an observation time of 28 days. In experiments with tumour-
bearing mice the observation time was limited by tumour
regrowth, and up to one death per seven mice was considered
acceptable, as occasional deaths were seen in non-drug-treated
groups during tumour regrowth. Any animals that became mori-
bund were terminated. MDAH-MCa-4 tumours (Silobrcic and
Suit, 1967) were grown from stocks stored in liquid nitrogen at the
fourth transplant generation. Mice were inoculated i.m. in the
gastrocnemius muscle with 20gl of a cell suspension (5 mg
packed cells) prepared from fifth-generation tumours by mincing
with crossed scalpels and extruding through a 200-mesh screen.
Tumour sizes were determined by measuring the diameter of the
tumour-bearing leg. Mice were treated when the tumour plus leg
diameter reached 10 mm (0.5 g tumour), using i.p. administration
(0.01 ml g-' body weight). Diameters were measured 3 days
week-' after treatment, and the tumour growth delay determined as
the difference between treated and control groups in the time to
reach 13 mm (1.5 g tumour). The statistical significance oftumour
growth inhibition was assessed by ANOVA using SAS for
Windows, with Dunnett's test to evaluate P-values for differences
between individual pairs of groups.
Tumour blood flow measurements
Blood flow was determined using the 99mTcO4 (pertechnetate)
wash-out method (Brown et al, 1988) as described previously
(Cliffe et al, 1994). Briefly, mice with 0.5-g tumours were
restrained without anaesthesia and tumours were injected with 2 x
5 gt pertechnetate (1 GBq ml-' in saline) using a 30-gauge needle.
Activity in the tumour-bearing volume was recorded for six mice
simultaneously, using a GE Starcam 3000 gamma camera.
Pertechnetate clearance was quantified using a single exponential
or weighted biexponential fit (Cliffe et al, 1994) to determine the
clearance rate constant k, which was corrected for radioactive
decay of99mTc (32 x 10- s-1).
Measurement of tumour necrosis
Mice were killed and the skin overlying the tumour was carefully
removed. The entire leg was fixed in 10% formalin and processed
for histology. Paraffin sections (4 ,um thick) were cut, orthogonally
to the long axis of the leg, from the distal, central and proximal
regions of each tumour, stained with haematoxylin and eosin
(H&E) and examined at 100 x magnification. An 81-square grid,
providing squares corresponding to 100 x 100 tm on the section,
was placed in the eyepiece, and each area was scored as predomi-
nantly viable tissue, predominantly necrotic tissue or other (which
included non-tumour tissue and artefacts caused by processing).
The whole area of each section was scored (approx 100 mm2 per
tumour).
RESULTS
Blood flow in MDAH-MCa-4 tumours was measured 4 h after
administration of DMXAA and/or 5-HT by determining the
kinetics of wash-out of intratumourally injected radioactive
pertechnetate (Figure 1). DMXAA alone caused dose-dependent
inhibition of blood flow, with 50% inhibition at 60 ,umol kg-'
(67% ofthe MTD). 5-HT (700 grmol kg-') by itselfhad little effect
on blood flow at 4 h, but when administered simultaneously with
DMXAA tumour blood flow inhibition was dramatically
increased, with 87% inhibition at only 20 gmol kg-' DMXAA
(Figure 1).
The time course ofblood flow inhibition (Figure 2) showed that
5-HT (700 ,umol kg-') alone gave weak and transient inhibition,
whereas DMXAA (70 tmol kg-') alone resulted in progressive
inhibition over 4 h with no recovery by 24 h in agreement with
previous data (Cliffe et al, 1994). The combination of DMXAA
and 5-HT was examined using a DMXAA dose of20 ,umol kg-' as
this gave similar inhibition to 70 tmol kg-' DMXAA alone at 4 h
in the experiment of Figure 1. The combination gave kinetics
different from DMXAA alone, with rapid inhibition (maximal
within 1 h) and slow reversal resulting in very variable flow by
26 h (Figure 2).
Histological examination of MDAH-MCa-4 tumours 12 h after
DMXAA treatment demonstrated engorgement of tumour blood
vessels (although without evident thrombosis) and extensive,
confluent haemorrhagic necrosis that tended to spare the superfi-
cial rim of the tumour and occasional isolated cords as seen in
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Figure 1 Blood flow in MDAH-MCa-4 tumours, measured as the rate
constant kfor clearance of pertechnetate, 4 h after i.p. administration of
DMXAA alone (0) or DMXAA simultaneously with 700 imol kg-' 5-HT (U).
Points are means ± s.e.m. for 6-9 tumours
n
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Figure 2 Kinetics of inhibition of blood flow in MDAH-MCa-4 tumours, as
determined with the pertechnetate clearance method, after treatment with
DMXAA alone (70 ,umol kg-'; *), 5-HT alone (700 ,imol kg-'; 0) or after co-
administration of DMXAA (20 ,mol kg-') and 5-HT (700glmol kg-'; *). Points
are means + s.e.m. for 6-12 tumours
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Figure 3 Residual viable tissue in MDAH-MCa-4 tumours, assessed
histologically. A Twelve hours after i.p. administration of DMXAA alone (@) or
DMXAA with 700 lmol kg-' 5HT (U). B At the indicated times after treatment
with DMXAA only (80 ,umol kg-'). Points are geometric means + s.e.m. for
8-11 tumours
other studies with DMXAA or FAA (Hill et al, 1992; Pedley et al,
1996, BC Baguley unpublished data). Scoring of necrosis indi-
cated a threshold of approximately 60,mol kg-1 for the necro-
tizing effect ofDMXAA (Figure 3A). 5-HT alone (700 gmol kg-')
caused qualitatively similar, but much less extensive, histological
changes at 12 h with a statistically significant (P = 0.0001)
increase in necrotic fraction from 8.8% to 38%. Co-administration
of 5-HT strongly enhanced the necrotizing effect of DMXAA
resulting in >99% necrosis at DMXAA doses of 60 gmol kg-' and
above. Based on the DMXAA dose required for 50% reduction of
viable tissue relative to the appropriate non-DMXAA control, the
dose-modifying factor (DMF) for 5-HT was 2.3. The fraction of
viable tissue increased rapidly (doubling time 1.0 day) between 1
and 4 days after treatment with DMXAA at 80 gmol kg-' (Figure
0
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Figure 4 Growth delay of MDAH-MCa-4 tumours after treatment of mice
with DMXAA alone (0), DMXAA with 700 lmol kg-' 5-HT (U), DMXAA with
200 gmol kg-' TIRA (O) or DMXAA with both 5-HT (700 ,mol kg-') and TIRA
(200 gmol kg-') (0). For each curve the highest DMXAA dose plotted
represents the MTD. Points are means ± s.e.m. for a single group of 6-9
tumours, except for DMXAA alone at 60 (three experiments pooled), 65 (five
experiments), 70 (12 experiments), 80 (12 experiments) and 90 (eight
experiments) ,tmol kg-'
3B). Histologically, regrowth was evident mainly as an enlarging
viable rim infiltrating irregularly from the tumour periphery with
little change in overall tumour diameter up to 4 days.
Inhibition by DMXAA of regrowth of MDAH-MCa-4 tumours
to 3 x treatment volume was also strongly enhanced by co-admin-
istration of 5-HT (Figure 4). The DMF for 5-HT, based on the
DMXAA dose required for a 5-day growth delay, was 2.0.
Importantly, the MTD for DMXAA in these experiments (90 ,umol
kg-') was unchanged by co-administration of 5-HT.
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The marked inhibition of tumour blood flow by DMXAA plus
5-HT suggested that this combination might augment the anti-
tumour activity of bioreductive drugs. The activity of TIRA
against the MDAH-MCa-4 tumour was therefore investigated in
combination with these blood flow inhibitors, alone and together,
by varying the DMXAA dose (Figure 4). Increased anti-tumour
activity was observed when TIRA (200 tmol kg-') was adminis-
tered 15 min before DMXAA, lowering the DMXAA dose
required for a 5-day growth delay by a factor of 1.8. A further
increase in activity was observed when 5-HT (700 gmol kg-') was
added to this combination (DMF = 2.6 relative to DMXAA alone).
However, host toxicity was also increased with these combina-
tions, giving MTD values for DMXAA of 60 tmol kg-' when
combined with TIRA, and 40 lmol kg-' with 5-HT plus TIRA,
compared with 90 gmol kg-' for DMXAA alone. Thus, whereas
adding 5-HT to DMXAA gave a therapeutic advantage, this was
not the case when TIRA was included.
In separate experiments (summarized in Table 1) the anti-
tumour activity and host toxicity of DMXAA/5-HT/TIRA combi-
nations was examined by varying the dose ofTIRA up to the toxic
limit, using fixed doses of the blood flow inhibitors (DMXAA at
80 ,umol kg-1 and/or 5-HT at 700 .tmol kg-'). These experiments
confirmed the increase in anti-tumour activity of DMXAA when
combined with 5-HT. Addition of DMXAA to TIRA lowered the
maximum dose of TIRA that could be tolerated from 300 to 200
,tmol kg-', but anti-tumour activity was significantly increased at
the MTD. 5-HT by itself had no effect on the MTD ofTIRA, and
did not enhance anti-tumour activity. Addition of both 5-HT and
DMXAA to TIRA enhanced host toxicity markedly, without
increasing the maximal anti-tumour activity significantly over that
for TIRA/DMXAA combinations without 5-HT. The increase in
host toxicity ofTIRA on addition of5-HT/DMXAA was also seen
in non-tumour-bearing C3H/HeN mice, with the TIRA MTD
decreasing from 300 to 100 tmol kg-' when combined with
DMXAA (80 tmol kg-') and 5-HT (700jtmol kg-').
The interaction of another bioreductive drug, the 2-nitroimida-
zole CI-1010, with DMXAA/5-HT was examined in the same way
(Table 1). DMXAA plus Cl-l010 gave a tumour response that was
clearly more than additive. In this case DMXAA did not change
the MTD for the bioreductive drug, but 5-HT increased the host
toxicity of CI- 1010 without enhancing anti-tumour activity. 5-HT
enhanced the maximum anti-tumour response to the DMXAA/CI-
1010 combination; the effect of 5-HT was statistically significant
in one of the two experiments, and was highly significant
(P=0.001) if both experiments were pooled. As for TIRA, inclu-
sion of 5-HT in the combination required considerable reduction
of the dose of the bioreductive drug with the MTD for CI-1010
decreasing from 940 gumol kg-' without blood flow modifiers to
280 ,umol kg-' in the triple combination. The toxicity ofthe combi-
nation was less severe if the bioreductive drug was administered
24 h after DMXAA/5-HT, giving a Cl-IO11 MTD of 350 tmol
kg-'. However, the anti-tumour activity with this timing (growth
delay 10.8 ± 2.4 days) was not as great as when the compounds
were co-administered.
The results with a third bioreductive drug, the dinitrobenzamide
mustard SN 23816, were distinctly different in that host toxicity
was little affected by co-administration of DMXAA and 5-HT,
either individually or together (Table 1). At the MTD for SN
23816, DMXAA provided a significant increase in anti-tumour
activity, with an average growth delay of 11 days for this combina-
tion, and this was increased further to 26.5 days (average of two
Table 1 Anti-tumour activity (MDAH-MCa-4 tumour) and host toxicity of
bioreductive drugs in combination with DMXAA (80 ,umol kg-') and/or 5-HT
(700 ,umol kg-'). Compounds were administered simultaneously i.p.
Bioreductive Blood flow BD MTDa Tumour growth delay
drug (BD) inhibitor (gmol kg-') (days)b
Expt 1 Expt 2
None DMXAA - 4.4+ 1.3c 4.0+ 1.1
5HT - 0.7 ± 0.8 -2.9 + 0.7
DMXAA + 5-HT - 10.3+ 1.8 14.1 + 3.0
TIRA None 300 2.5 + 0.7 1.5 + 1.0
DMXAA 200 13.0+ 1.9 13.4±2.3
5HT 300 2.7 + 1.4
DMXAA+5-HT 75 16.7± 1.9 14.1 +4.7
Cl-1010 None 940 3.6+ 1.1 0.1 + 1.1
DMXAA 940 11.2 ± 1.4 8.6+ 1.1
5HT 500 3.2 + 1.6
DMXAA + 5-HT 280 19.7 + 6.0 19.4 + 2.8
SN 23816 None 300 3.5 + 0.7 3.5 ± 1.2
DMXAA 300 9.6+ 1.7 13.3+ 2.2d
5HT 225 3.8 ±1.2 0.0+0.9
DMXAA + 5-HT 225 22 + 3 31 6
aMaximum tolerated dose of the bioreductive drug in the indicated
combination, as assessed in tumour-bearing mice. bDetermined at the
indicated MTD for the bioreductive drug, using approximately 1.3-fold dose
increments. cMean + s.e.m., for groups of seven mice unless otherwise
indicated. dEleven mice. Excludes one large response (growth delay 98
days).
experiments) by inclusion of 5-HT. The effect of 5-HT, when
combined with SN 23816 plus DMXAA, was statistically signifi-
cant in both experiments (P < 0.01), whereas 5-HTby itselfdid not
increase the activity ofSN 23816. The effect ofvarying 5-HT dose
in the combination treatment was investigated in separate experi-
ments (Table 2). Host toxicity, as assessed by body weight change,
was not increased by 5-HT (approximately 9% weight loss in all
groups). The effect of 5-HT on anti-tumour response was statisti-
cally significant, in both experiments, only at the highest dose of
5-HT. Anti-tumour activity was diminished when administration
of the bioreductive drug was delayed (Table 2); this decrease was
statistically significant at 24 h but not at 2 h.
DISCUSSION
For each end point investigated (blood flow inhibition, necrosis
and growth inhibition), the dose-response relationship for activity
of DMXAA against MDAH-MCa-4 tumours was non-linear, with
a threshold at about half of the MTD. This feature of DMXAA
(and FAA) activity has been noted in many other studies. The
requirement for doses so close to the toxic limit suggests that it
will be difficult to demonstrate the activity ofDMXAA in humans
if its therapeutic ratio is similar to that in mice. The combination
with exogenously administered 5-HT is therefore of particular
interest as the anti-tumour activity of DMXAA is enhanced
strongly, with little or no increase in host toxicity. The increase in
anti-tumour activity ofDMXAA by co-administration of5-HT has
been observed with all three tumours investigated to date, namely
the mammary carcinoma MDAH-MCa-4 in this study, colon 38
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Table 2 Activity of SN 23816 (200 pmol kg-1) against the MDAH-MCa-4
tumour in combination with DMXAA (80 pmol kg-1) and 5-HT: influence of
5-HT dose and timing. DMXAA and 5-HT were administered simultaneously
5-HT dose Time (h) between Tumour growth delay (days)a
(,umol kg-1) DMXAA/5-HT
and SN 23816 Expt 1 Expt 2
0 0 7.5±1.2 9.9±1.2
1 0 8.0 + 1.6 12.8 + 2.7
50 0 11.0 ± 1.4 9.2 ± 1.8
200 0 14.7 + 2.3 10.5 + 1.5
700 0 22.6 ± 4.9 21.2 + 1.1
700 2 15.2+2.1
700 24 8.0 ±1.8
aMean + s.e.m. for groups of 5-7 mice.
tumours (Baguley et al, 1993) and LS174T human colon adenocar-
cinoma xenografts (Pedley et al, 1996). DMXAA/5HT resembles
the tubulin-binding agent combretastatin A-4 in its ability to
inhibit tumour blood flow at doses well below the MTD (Dark et
al, 1997), although no direct comparison has been made between
these antivascular therapies. The potential of 5-HT, perhaps in
combination with 5-HT3 receptor antagonists, to enhance the ther-
apeutic ratio of DMXAA in humans thus warrants investigation. It
would also be of interest to combine DMXAA with the new
tumour blood flow inhibitor KB-R8498, which appears to act as a
5-HT2 receptor agonist (Sekida et al, 1997).
The mechanism by which exogenous 5-HT enhances tumour
blood flow inhibition when combined with DMXAA is not known.
It may be that both agents have independent effects on the tumour
microvascular system. However, the observation that the 5-HT,
receptor antagonist cyproheptidine inhibits colon 38 tumour
necrosis by DMXAA or recombinant human TNF-a (Baguley et
al, 1993), and that the activity ofTNF-ox against the 5-HT-sensitive
Meth A fibrosarcoma is inhibited by 5-HT receptor antagonists
(Manda et al, 1988), led to the earlier suggestion that 5-HT might
act downstream from TNF-ux in mediating DMXAA effects
(Baguley et al, 1993). If this is the case, administered 5-HT might
augment this endogenous pathway. This is made less likely by
recent studies indicating that systemic concentrations of 5-HT (or
its oxidative metabolite 5-hydroxyindole acetic acid) are only
slightly elevated after DMXAA treatment, and that this elevation
is also observed following treatment with antivascular agents such
as vinblastine that do not act via TNF-a (Baguley et al, 1997). This
suggests that 5-HT elevation is a consequence rather than a cause
of the antivascular effects. A further, testable, hypothesis is that
hypoxia induced by the early blood flow effect ofexogenous 5-HT
augments TNF-ox induction by DMXAA.
There is some uncertainty as to whether the anti-tumour effects
of DMXAA or FAA are due exclusively to antivascular effects, or
whether immunomodulatory effects (Baguley and Ching, 1997)
make an independent contribution. In support of the latter view,
growth inhibition of murine colon tumours (but not antivascular
effects) is compromised by T-cell depletion (Pratesi et al, 1990;
Bibby et al, 1991) although similar studies by Ching et al (1992)
showed little loss of activity of either FAA or DMXAA against
colon 38 tumours in nude or thymectomized mice. Further, non-
vascularized tumour tissue is relatively insensitive to FAA-induced
killing in mice (Finlay et al, 1988; Zwi et al, 1989, 1990), and a
correlation has been demonstrated between blood flow inhibition
by FAA and growth delay using a range of non-immunogenic
mouse tumours (Hill et al, 1989). In the present study the effect of
5-HT on the anti-tumour effects of DMXAA was qualitatively
similar for all three end points examined (blood flow inhibition at 4
h, necrosis at 12 h and growth delay to 3 x treatment size), although
the magnitude of the dose-modifying effects (>3, 2.3 and 2.0
respectively) were not identical. The greater effect on blood flow at
4 h does not necessarily point to a non-vascular anti-tumour mech-
anism as greater recovery of flow is seen after the DMXAA/5-HT
combination than for DMXAA alone (Figure 2) at a dose giving
equivalent effects at 4 h. Thus, the data are broadly consistent with
the view that ischaemic damage resulting from the antivascular
effects of DMXAA or DMXAA/5-HT mediates the observed anti-
tumour effect, at least in non-immunogenic tumours.
Rapid tumour regrowth despite extensive haemorrhagic necrosis
has been noted in a numberofstudies with DMXAA or FAA (Bibby
et al, 1991; Ching et al, 1992; Hill et al, 1992; Pedley et al, 1994,
1996), suggesting that residual viable tissue may regrow rapidly
after treatment. In the present study large numbers of sections were
scored to enable measurement of small amounts of residual viable
tissue, thus enabling comparison between the two end points. The
growth delay expected if this is due only to the time required for
regrowth ofthe viable tissue to the treatment size is given by
GD=N+ td log VO
0.301 V
where t, is the doubling time ofthe viable tissue after treatment, V0
is the fraction of viable tissue in control tumours and Vis the frac-
tion ofviable tissue at the nadir N(approximately 1 day after treat-
ment, Figure 3). Using the values of V0 and Vfrom Figure 3A, and
the measured value of td (1.0 day) from Figure 3B, this gives a
predicted growth delay of 6.0 days (observed 4.9 ± 0.3 days;
Figure 4) following DMXAA alone at 80 tmol kg-' and a
predicted growth delay of 5.8 days (observed 5.1 ± 1.0 days)
following DMXAA (40 gmol kg-') plus 5-HT. Thus, the necro-
tizing effect is sufficient to account for the observed growth delay.
It is of interest that the doubling time of viable tissue after treat-
ment of 0.5-g tumours, although not specified very accurately by
the data of Figure 3B, appears to be shorter than that for control
MDAH-MCa-4 tumours in the size range 0.5-1.5 g (td, 5 days),
suggesting rapid repopulation of necrotic regions following
DMXAA treatment. This suggests the potential for using cycle-
selective chemotherapy shortly after DMXAA treatment.
Previous studies have shown that DMXAA enhances the thera-
peutic activity of the hypoxia-activated bioreductive drugs TIRA
(Cliffe et al, 1994), CI-lOlO (Vincent et al, 1997), SN 23816
(Cliffe et al, 1994; Wilson and Pruijn, 1995), AQ4N (Wilson et al,
1996) and the hypoxia-selective alkylating agent melphalan
(Pruijn et al, 1997). The present study demonstrates that co-admin-
istration of TIRA, CI-1010 or SN 23816 with DMXAA provides
enhanced activity against the MDAH-MCa-4 tumour. It is
presumed that these interactions result primarily from induction of
hypoxia after DMXAA treatment, although it has been shown with
melphalan that decreased extracellular pH and entrapment of the
alkylating agent as a result offalling blood flow also contribute to
the increased anti-tumour activity (Pruijn et al, 1997). Inhibition of
tumour blood flow after DMXAA appears to be essentially irre-
versible (Figure 2), as noted previously (Cliffe et al, 1994), in
which case it might be expected that the cells dependent on these
vessels would be fated to die as a result of ischaemic damage and
that the addition of a bioreductive drug would have no further
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effect. The observation that bioreductive drugs increase tumour
cell killing therefore argues that there is an important (treatment-
limiting) population of tumour cells that are only transiently
hypoxic after DMXAA treatment and that eventually contribute to
tumour regrowth.
Addition of 5-HT to DMXAA-bioreductive drug combinations
provides further increases in anti-tumour activity (Figure 4 and
Table 1). The kinetics of blood flow inhibition after DMXAA/5-
HT combinations (early inhibition with some reversal) is different
from that after DMXAA alone (Figure 2), and might provide more
of the transient hypoxia that can be exploited by bioreductive
drugs (Brown and Koong, 1991; Brown and Lemmon, 1991).
Studies of changes in blood flow (and hypoxia) at the micro-
vascular level would assist in clarifying these issues.
Although 5-HT enhances the anti-tumour activity of
DMXAA-bioreductive drug combinations, in the case of TIRA or
CI-1010 there is an approximately similar increase in host toxicity
so that little therapeutic advantage is obtained. There is evidence
that the radioprotective effect of5-HT in mice is due to induction of
normal tissue hypoxia (Bacq, 1965), which might also be respon-
sible for the enhancement of bioreductive drug toxicity in the
present study. However, not all bioreductive drugs suffer from this
problem; the anti-tumour effect of the dinitrobenzamide mustard
SN 23816 with DMXAA is enhanced to a greater extent than is
host toxicity by co-administration of5-HT, resulting in a significant
therapeutic gain (Table 1). It is not clearwhy the effect on host toxi-
city is less for SN 23816 than for the other bioreductive drugs. The
oxygen dependence ofTIRA cytotoxicity is quantitatively different
than for RB 6145/RSU 1069 or SN 23816, with activation of the
latter nitro compounds requiring much more severe hypoxia than is
the case for TIRA (Koch, 1993; Wilson et al, 1994). On this basis,
both SN 23816 and CI-l010 might be expected to be less sensitive
than TIRA to induction of hypoxia in normal tissues. The greater
host toxicity enhancement by 5-HT for CI-1010 than for SN 23816
may indicate that different normal tissues (with different blood
flow responses to 5-HT) are dose limiting for the two agents.
In conclusion, the present study demonstrates that co-adminis-
tration of 5-HT with DMXAA provides marked tumour blood
flow inhibition at well-tolerated doses, and that this combination is
therapeutically superior to DMXAA alone as an antivascular
tumour therapy in mice. Further improvement in therapeutic effect
is achievable by combining DMXAA/5-HT with the bioreductive
drug SN 23816, although this advantage is not obtained with the
other two bioreductive drugs tested. Combination of DMXAA
with 5-HT, and with appropriate bioreductive drugs, may be useful
for improving the efficacy of this novel antivascular agent in
clinical application.
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